Gilead Sciences signed a contract with four Indian pharmaceutical companies to produce its medication ‘Remdesivir’ which has been found effective in treatment of some COVID-19 patients.

Pharmaceutical major Dr Reddy’s has reported 22 percent jump in profit before tax for fourth quarter and 10 percent growth in revenue.

Gilead Sciences CEO Daniel O’Day said on Friday that the company is focused on experimental coronavirus drug that is affordable and widely accessible.

Market analyst Ashwani Gujral is bullish for the day with five BUY Calls for stocks.

ABBOTT India is a good long term investment for Indian investors as per Nirali Shah, SAMCO Research.

Lupin and Aurobindo Pharma have been recommended for hold by research house Prabhudas Lilladher. Target price for Aurobindo Pharma has been suggested Rs 511.